[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Saúde e medicinaOne-Off3aManifold MarketsSem KYCDados de resolução verificadosRazoavelmente calibradoPrevisão da comunidade atual2030 36.4%Líder entre 6 opções
Previsores
21
Tipo de pergunta
multiple choice
Metodologia
Play-money forecasting platform
Tipo de fonte
Previsão
Variação 7d
0.0 pts
Dados do mercado
Atualizado há 4 horas
Desatualizado18/11/23, 22:14 UTC1/01/30, 04:59 UTC
Tendências
Regras
Inspired by https://manifold.markets/AaronKaufman/will-any-fdaapproved-glp1-agonists and will use the same criteria:
- GLP-1 agonists, such as semaglutide (ozempic/wegovy), tirzepatide (mounjaro), and dulaglutide (Trulicity), are becoming popular for weight loss and Type-2 diabetes treatment.
- This market resolves positively if any approved GLP-1 agonists for either T2D or weight loss are withdrawn from the market due to safety reasons by the listed date.
- This applies either if the FDA mandates it or if the company withdraws the drug voluntarily.
